No. 015 · GH & Growth · Growth Hormone
Hexarelin
Also known as: ExamorelinEP-23905
- Not FDA approved
- WADA ✗ S2
2D structure from PubChem CID 6918297 (Examorelin), matched by exact name. Hydrogens on carbon are implied.
No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.
Quick answers
- What is Hexarelin?
- The most potent synthetic GHRP, producing the largest single GH pulse among its class.
- How strong is the evidence for Hexarelin?
- Tier B (small human studies) on the peptidemeta evidence scale. Human data are limited to small pharmacological studies; no approved use.
- Is Hexarelin FDA-approved?
- No. Hexarelin is not approved by the FDA for any use.
- Is Hexarelin banned in sport?
- Yes. Hexarelin is prohibited in sport by the World Anti-Doping Agency under S2 (peptide hormones, growth factors, related substances and mimetics).
- How does Hexarelin work?
- Hexarelin is a synthetic hexapeptide and the most potent GHS-R1a agonist, producing the largest acute GH pulse among all GHRPs. It acts through both pituitary and hypothalamic pathways to amplify GH release.
- What is known about the safety of Hexarelin?
- Human trial data available. Desensitization of GH response occurs with prolonged daily use.
Last reviewed · editorial policy · markdown
Evidence
- D In vitro
- C Animal
- B Human pilot
- A RCT
- S Approved
TIER B — Human data limited to small, open-label or pharmacokinetic studies.
Human data are limited to small pharmacological studies; no approved use.
Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.
At a glance
- Routes studied
- Subcutaneous, Intramuscular Routes used in published research
- FDA
- Not approved
- WADA
- Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
Overview
The most potent synthetic GHRP, producing the largest single GH pulse among its class. Its use is limited by desensitization at prolonged high doses and notable cortisol/prolactin elevation.
Research status Phase I/II clinical trials; documented receptor desensitization with prolonged use
Mechanism
Hexarelin is a synthetic hexapeptide and the most potent GHS-R1a agonist, producing the largest acute GH pulse among all GHRPs. It acts through both pituitary and hypothalamic pathways to amplify GH release. It also binds the CD36 scavenger receptor on cardiomyocytes, conferring cardioprotective effects independent of GH.
Effects reported in research
Reported outcomes, not promises. Human data are limited to small studies, and many of these findings are preclinical.
- Strongest GH release among GHRPs
- Cardioprotective signaling
- Increased IGF-1 output
- Enhanced fat oxidation
Safety & unknowns
Human trial data available. Desensitization of GH response occurs with prolonged daily use. Elevates cortisol and prolactin more than other GHRPs. Common side effects: flushing, hunger, water retention. Not FDA-approved.
Unknowns. No randomized controlled trials have been published. Small studies cannot detect uncommon or long-term harms.
Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.
Studies [0]
No studies cited for this entry yet.
Status sources
Sources behind the tier, regulatory status, sequence and dates on this page.
- PubMed: hexarelin pubmed.ncbi.nlm.nih.gov
- WADA 2026 Prohibited List wada-ama.org
Cite this entry
peptidemeta. (2026). Hexarelin. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/hexarelin/
@misc{peptidemeta-hexarelin,
title = {Hexarelin},
author = {{peptidemeta}},
year = {2026},
howpublished = {\url{https://peptidemeta.com/p/hexarelin/}},
note = {Accessed 2026-11-08}
} Accessed date reflects when you opened this page. Cite primary studies for scientific claims.